Product logins

Find logins to all Clarivate products below.


Eosinophilic Esophagitis | Treatment Algorithms: Claims Data Analysis | US | 2020

Eosinophilic Esophagitis (EoE) is a chronic, allergic inflammatory disease of the esophagus caused by an accumulation of eosinophils leading to a difficulty in swallowing food with the potential for dangerous food impaction. Topical steroids and proton pump inhibitors are the mainstays of clinical management for EoE, however the indication has no official therapy approvals by FDA. EoE has an active pipeline that will further drive off-label use until novel therapies with unique MOAs reach the market. As the EoE current treatment landscape continues to evolve, this report offers insights from real-world claims data into prescribing trends in EoE to help new players to better understand current treatment practices in EoE and help define the market niche for their emerging product.

QUESTIONS ANSWERED

  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed EoE patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed EoE patients?
  • How have steroids and proton pump inhibitors been integrated into the treatment algorithm, and what are their source of business?
  • What percentage of EoE patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of EoE patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?

CONTENT HIGHLIGHTS

Geographies

United States

Real World data

Longitudinal patient-level claims data analysis

Key Drugs Covered

Fluticasone, budesonide, ciclesonide, prednisone, dexlansoprazole, omeprazole, esomeprazole, lansoprazole, rabeprazole, and pantoprazole

Key Analysis provided

  • Brand/therapy usage across longitudinal patient sample
  • Newly diagnosed patient analysis
  • Treatment initiation and progression
  • Line of therapy analysis
  • Combination therapy analysis
  • Source of business for recently treated patients
  • Persistency and compliance analysis
  • Product-level patient flowcharts

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Related Market Assessment Reports

Report
Eosinophilic Esophagitis – Unmet Need – Unmet Need – Eosinophilic Esophagitis (US/EU)
Standard treatments for eosinophilic esophagitis (EoE) typically include proton pump inhibitors (PPIs) and swallowed topical steroids. Although these therapies can alleviate EoE symptoms, their…
Report
Breast Cancer – Geographic Focus: China – China In-Depth – Breast Cancer
China’s breast cancer market continues to evolve rapidly, driven by rising incidence and expanding systemic treatment options. Several new and emerging therapies are expected to gain approval for…
Report
Chronic Obstructive Pulmonary Disease – Unmet Need – Unmet Need – Severe to Very Severe Chronic Obstructive Pulmonary Disease (US EU)
The severe to very severe chronic COPD market is crowded, with numerous LAMA, LABA/ICS, LABA/LAMA, and triple LABA/LAMA/ICS inhalers competing for use. Although dual and triple longacting…
Report
Diabetic Macular Edema / Diabetic Retinopathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Diabetic Macular Edema (US)
Diabetic macular edema (DME) is a serious complication of diabetic retinopathy caused by persistently elevated blood glucose levels. Without timely treatment, DME can progress to significant vision…
Report
Multiple System Atrophy – Unmet Need – Multiple System Atrophy (US/EU) – Unmet Need – Multiple System Atrophy (US/EU)
Multiple system atrophy (MSA) is a rare, rapidly progressing neurodegenerative synucleinopathy that disrupts movement, balance, and autonomic function. Current management comprises only symptomatic…